Effect of Intensive Therapy Associated With CSII on β-cell Function With Newly Diagnosed Type 2 Diabetes

Browse trials for

• Diabetes Mellitus 10,925
• Diabetes Mellitus, Type 2 9,359

Keywords

• ype 2 diabetes mellitus, continuous subcutaneous insulin infusion,
• α-lipoic acid ,rosiglitazone ,metformin，therapy

Diabetes Mellitus

10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.

This study's planned enrollment of 400 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.

Lead sponsor

Sun Yat-sen University is the lead sponsor of 1,644 studies on the registry; 602 are open to participants now.

Study arms

• Active comparator
  CSII

  CSII: Patients in continuous subcutaneous insulin infusion group received insulin analogue with an insulin pump along.

  Drug: CSII,ALA,MET,RSG

• Active comparator
  ALA

  ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD.

  Drug: CSII,ALA,MET,RSG

• Active comparator
  RSG

  RSG:CSII combined with three months rosiglitazoneor 4mg QD.

  Drug: CSII,ALA,MET,RSG

• Active comparator
  MET

  MET:CSII combined with metformin 500mg BID-TID.

  Drug: CSII,ALA,MET,RSG

Interventions

• DrugCSII,ALA,MET,RSG

  CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.

Primary outcomes

1. beta cell function;fast blood glucose;

   Time frame: 2011/05

Publications

• Liu L, Ke W, Wan X, Zhang P, Cao X, Deng W, Li Y. Insulin requirement profiles of short-term intensive insulin therapy in patients with newly diagnosed type 2 diabetes and its association with long-term glycemic remission. Diabetes Res Clin Pract. 2015 May;108(2):250-7. doi: 10.1016/j.diabres.2015.02.011. Epub 2015 Feb 21. PubMed 25765670 ↗